Category: Press Releases
NOVOS Reports Effectiveness Against DNA Damage
June 15, 2022
NEW YORK – June 15, 2022 – NOVOS, a company that develops science-based products to slow down aging, announced results of two studies demonstrating that the combination of ingredients in
Maximon Startup AVEA Closes 2.5M CHF Funding Round
June 1, 2022
The longevity company builder Maximon has concluded a financing round for AVEA at this year’s World Economic Forum. The press release is included here. ZUG, SWITZERLAND — AVEA, the longevity
First Cohort Dosed in Phase 1b Trial of BioAge’s BGE-105
April 19, 2022
BioAge, a biotechnology company that intends to target aging on the molecular level, has completed a Phase 1b clinical trial of BGE-105, a small molecule that influences muscular metabolism. Below
Kizoo Company Elastrin Closes $10M Funding Round
April 7, 2022
The well-known biotechnology holding company Kizoo has engaged in another funding round, this time for Elastrin Therapeutics, a company that focuses on returning stiff tissues to their natural state. The
Insilico Medicine Identifies New Aging Targets
March 30, 2022
Insilico Medicine, which uses AI for drug discovery, has identified potential dual-purpose therapeutic targets that are implicated in aging and age-associated diseases using artificial intelligence and a Hallmarks of Aging
Kizoo and Revel Announce $8.4 Million Seed Round
March 18, 2022
Revel Pharmaceuticals, a holding of Kizoo Technology Capital, has announced that it is seeking $8.4 million dollars in investment funding in order to develop its enzyme-based approach towards ending age-related
New Partnership Between Molecule, Apollo, and VitaDAO
February 21, 2022
Combining a Web3 IP market, venture capital, and a decentralized autonomous organization (DAO), three companies have banded together to create a new decentralized science ecosystem. The full press release is
Novartis Licenses mTOR Analogs to Cambrian Biopharma
February 17, 2022
Following the efforts of Adicet Bio, formerly resTORbio, to create therapies based on the mTOR pathway, Cambrian Biopharma is working with Novartis to use this pathway in order to increase
Altos Labs’ $3 Billion Launch to Reverse Cellular Aging
January 20, 2022
In September 2021, we reported that Altos Labs was about to launch an ambitious project to develop partial cellular reprogramming to the point where it could be safely used in
Ichor Life Sciences Acquires Woodland Biosciences, Inc.
December 22, 2021
Woodland Biosciences, which studies metabolism and cancer, has joined the holdings of Ichor Life Sciences. Ichor intends to use Woodland’s expertise and research to increase the specializations of its pharmacological
New Partnership Between Forever Healthy and Buck Institute
December 15, 2021
Yet another group has formed to advance early-stage biotechnology research. This time, the Forever Healthy Foundation, founded by Michael Greve, has formed a $5 million partnership with the Buck Institute
Apollo Health Ventures Closes $180 Million Fund
December 2, 2021
Apollo Health Ventures, a venture capitalist firm focusing on rejuvenation biotechnology, has raised $180 million in order to fund companies developing interventions that target age-related diseases. We have included the
Longevica to Launch an Open Research Platform
November 29, 2021
Longevica, a company focused on the biology of aging, has raised $2.5 million dollars for its platform that it hopes will accelerate life extension research. We have included the full
Maximon Launches Longevity Co-Investment Fund
October 7, 2021
The venture capitalist firm Maximon has announced a new longevity-focused fund that focuses on financing early-stage biotechnology companies that increase human healthspan. The firm intends to invest 100 million Swiss
Transhuman Coin Debuts on International Markets
September 30, 2021
A novel cryptocurrency, Transhuman Coin, has recently announced its debut. When a transaction occurs, this coin is automatically distributed back into funding its own growth and the development of research
NOVOS Reports Effectiveness Against DNA Damage
June 15, 2022
NEW YORK – June 15, 2022 – NOVOS, a company that develops science-based products to slow down aging, announced results of two studies demonstrating that the combination of ingredients in its products, NOVOS Core and NOVOS Boost, protect against DNA damage and cellular aging (senescence). A
Maximon Startup AVEA Closes 2.5M CHF Funding Round
June 1, 2022
The longevity company builder Maximon has concluded a financing round for AVEA at this year’s World Economic Forum. The press release is included here. ZUG, SWITZERLAND — AVEA, the longevity supplement startup with the aim to improve healthspan, announces the closing of a 2.5 million CHF
First Cohort Dosed in Phase 1b Trial of BioAge’s BGE-105
April 19, 2022
BioAge, a biotechnology company that intends to target aging on the molecular level, has completed a Phase 1b clinical trial of BGE-105, a small molecule that influences muscular metabolism. Below is the company’s full press release. RICHMOND, Calif.–(BUSINESS WIRE)– BioAge Labs, Inc., a biotechnology company developing
Kizoo Company Elastrin Closes $10M Funding Round
April 7, 2022
The well-known biotechnology holding company Kizoo has engaged in another funding round, this time for Elastrin Therapeutics, a company that focuses on returning stiff tissues to their natural state. The full press release is included here. Greenville, SC, U.S, April 7, 2022 – Elastrin Therapeutics Inc.,
Insilico Medicine Identifies New Aging Targets
March 30, 2022
Insilico Medicine, which uses AI for drug discovery, has identified potential dual-purpose therapeutic targets that are implicated in aging and age-associated diseases using artificial intelligence and a Hallmarks of Aging framework. The full press release is included here. March 29, 2022, New York (11AM ET) —
Kizoo and Revel Announce $8.4 Million Seed Round
March 18, 2022
Revel Pharmaceuticals, a holding of Kizoo Technology Capital, has announced that it is seeking $8.4 million dollars in investment funding in order to develop its enzyme-based approach towards ending age-related diseases. The full press release is included below. Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed
New Partnership Between Molecule, Apollo, and VitaDAO
February 21, 2022
Combining a Web3 IP market, venture capital, and a decentralized autonomous organization (DAO), three companies have banded together to create a new decentralized science ecosystem. The full press release is included here. Feb. 21, 2022, Switzerland — Molecule, a biotech IP Web3 marketplace, announces a tripartite
Novartis Licenses mTOR Analogs to Cambrian Biopharma
February 17, 2022
Following the efforts of Adicet Bio, formerly resTORbio, to create therapies based on the mTOR pathway, Cambrian Biopharma is working with Novartis to use this pathway in order to increase healthspan and lifespan. The full press release is included here. NEW YORK, Feb. 16, 2022 /PRNewswire/ — Cambrian
Altos Labs’ $3 Billion Launch to Reverse Cellular Aging
January 20, 2022
In September 2021, we reported that Altos Labs was about to launch an ambitious project to develop partial cellular reprogramming to the point where it could be safely used in humans to reverse cellular aging. That launch has now officially started, and Altos Labs is shaping
Ichor Life Sciences Acquires Woodland Biosciences, Inc.
December 22, 2021
Woodland Biosciences, which studies metabolism and cancer, has joined the holdings of Ichor Life Sciences. Ichor intends to use Woodland’s expertise and research to increase the specializations of its pharmacological division. The full press release is provided here. LaFayette, N.Y. — Ichor Life Sciences, a premium preclinical
New Partnership Between Forever Healthy and Buck Institute
December 15, 2021
Yet another group has formed to advance early-stage biotechnology research. This time, the Forever Healthy Foundation, founded by Michael Greve, has formed a $5 million partnership with the Buck Institute in order to fund rejuvenation biotechnology. The full press release is included here. Forever Healthy and
Apollo Health Ventures Closes $180 Million Fund
December 2, 2021
Apollo Health Ventures, a venture capitalist firm focusing on rejuvenation biotechnology, has raised $180 million in order to fund companies developing interventions that target age-related diseases. We have included the full press release below. Apollo Health Ventures Closes $180 Million Fund to Drive Breakthrough Innovations Combating
Longevica to Launch an Open Research Platform
November 29, 2021
Longevica, a company focused on the biology of aging, has raised $2.5 million dollars for its platform that it hopes will accelerate life extension research. We have included the full press release below. Longevica to Launch an Open Research Platform to Accelerate the Discovery of Life
Maximon Launches Longevity Co-Investment Fund
October 7, 2021
The venture capitalist firm Maximon has announced a new longevity-focused fund that focuses on financing early-stage biotechnology companies that increase human healthspan. The firm intends to invest 100 million Swiss francs into such companies. The full press release is presented below. Maximon has launched its 100
Transhuman Coin Debuts on International Markets
September 30, 2021
A novel cryptocurrency, Transhuman Coin, has recently announced its debut. When a transaction occurs, this coin is automatically distributed back into funding its own growth and the development of research into cures for various disabilities, including age-related disorders. We at lifespan.io support Transhuman Coin donations on